Epigenetic regulation of papillary thyroid carcinoma by long non-coding RNAs

Lin, Rui-Qing; Yang, Shijie; Jia, Yan; Wu, Jiacheng; Xu, Zenglin; Zhang, Hong

doi:10.1016/j.semcancer.2021.03.027

Cited by 36 publications

(21 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The close interaction between lncRNAs and other cellular molecules, including DNA, mRNA, and microRNA, has been reported to be involved in multiple diseases, including cardiovascular diseases, cancers, and metabolic diseases [5][6][7][8], and has attracted increasing attention. For instance, aging-regulated lncRNAs were found to act as antiapoptotic agents in cardiomyocytes [9], and more recently, Lin et al discovered that several lncRNAs are involved in papillary thyroid carcinoma by sponging microRNAs and modulating the PI3K/Akt and Wnt signaling pathways [10]. Moreover, accumulating evidence indicates the prognostic value of aberrantly expressed lncRNAs in multiple biological and pathological processes.…”

Section: Introductionmentioning

confidence: 99%

A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) has been the major cause of tumor-associated mortality in recent years and has a poor prognosis. Pyroptosis is regulated via the activation of inflammasomes and participates in tumorigenesis. However, the effects of pyroptosis-related lncRNAs (PRlncRNAs) on LUAD have not yet been completely elucidated. Therefore, we attempted to systematically explore patterns of cell pyroptosis to establish a novel signature for predicting LUAD survival. Based on TCGA database, we set up a prognostic model by incorporating PRlncRNAs with differential expression using Cox regression and LASSO regression. Kaplan-Meier analysis was conducted to compare the survival of LUAD patients. We further simplified the risk model and created a nomogram to enhance the prediction of LUAD prognosis. Altogether, 84 PRlncRNAs with differential expression were discovered. Subsequently, a new risk model was constructed based on five PRlncRNAs, GSEC, FAM83A-AS1, AL606489.1, AL034397.3 and AC010980.2. The proposed signature exhibited good performance in prognostic prediction and was related to immunocyte infiltration. The nomogram exactly forecasted the overall survival of patients and had excellent clinical utility. In the present study, the five-lncRNA prognostic risk signature and nomogram are trustworthy and effective indicators for predicting the prognosis of LUAD.

show abstract

Section: Introductionmentioning

confidence: 99%

A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…LncRNAs are emerging as key molecules with the potential to provide many molecular phenotypic characteristics of DTC and to serve as novel targets for DTC [43]. Our study showed that GLTC is highly expressed in DTC and that high expression of either GLTC is closely linked to unfavorable outcomes, suggesting that the combination of GLTC is a potential prognostic marker for DTC diagnosis and a promising DTC therapeutic target.…”

Section: Discussionmentioning

confidence: 64%

LncRNA GLTC targets LDHA for succinylation and enzyme activity to promote differentiated thyroid cancer progression and radioiodine resistance

Shi

Duan²,

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

Long noncoding RNA (lncRNA) dysregulation has been associated with the development and progression of many human cancers. Lactate dehydrogenase A (LDHA) enzyme activity is also crucial for cancer development, including that of differentiated thyroid cancer (DTC). Nevertheless, it remains unclear whether specific lncRNAs can regulate LDHA activity in cancer progression. Through screening, we identified an LDHA-interacting lncRNA, GLTC, which is required for increased aerobic glycolysis and cell proliferation in DTC. GLTC was significantly upregulated in DTC tissues compared with nontumorous thyroid tissues. High expression of GLTC was correlated with progressive histologic type, extent of distant metastases, larger tumor size, and poorer prognosis. Mass spectrometry revealed that GLTC, as a binding partner of LDHA, promotes the succinylation of LDHA on lysine-155 (K155) via its competitive inhibition of the interaction between SIRT5 and LDHA, thereby promoting LDHA enzymatic activity. Overexpression of the succinylation-mimic LDHAK155E mutant restored glycolytic metabolism and proliferation in cells that had ceased metabolic reprogramming and proliferation due to GLTC depletion. Interestingly, GLTC inhibition abrogated the effects of succinylated LDHA K155 on radioiodine (RAI) resistance in vitro and in vivo. Taken together, our results indicate that GLTC plays an oncogenic role and is an attractive RAI sensitization target for the treatment of DTC.

show abstract

“…Among them, we noticed the PI3K-Akt signaling pathway, which play a importent role in cell proliferation and migration in PTC ( 32 – 34 ). Many lncRNAs also play a significant regulatory role in PI3K-Akt signaling pathway in PTC ( 35 ), such as lncRNA XIST ( 36 ), lncRNA ABHD11-AS1 ( 37 ), lncRNA TTN-AS1 ( 38 ), etc. However, these lncRNAs were not found in our results for the same reason.…”

Section: Discussionmentioning

confidence: 99%

Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto’s Thyroiditis

Ding

Peng

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) play a significant role in cancer biology. This study aimed to determine the roles of lncRNAs in establishing the differences in clinical features between patients with papillary thyroid carcinoma (PTC) without Hashimoto’s thyroiditis (HT) and patients with PTC and HT. In the present study, we detected the differentially expressed lncRNAs between tumor tissues of patients with PTC with or without HT through lncRNA microarrays. The data were verified and analyzed through qRT-PCR, cell viability, cell cycle and bioinformatics analyses. We found that 1031 lncRNAs and 1338 mRNAs were abnormally expressed in 5 tissue samples of PTC complicated with HT [PTC/HT (+)] compared with 5 samples of PTC without HT [PTC/HT (-)]. Gene Ontology and pathway analyses of the mRNAs suggested that several biological processes and pathways, particularly immune system processes, were induced in the PTC/HT (+) tissues. Twenty lncRNAs were verified in 31 PTC/HT (+) and 64 PTC/HT (-) specimens by qRT-PCR, and the results were consistent with the microarray data. Specifically, ENST00000452578, a downregulated lncRNA in PTC/HT(+), was negatively correlated with the tumor size. Cell viability assays revealed that ENST00000452578 could inhibit cell proliferation. Our results indicate that lncRNAs and mRNAs play an important role in establishing the different clinical characteristics between patients with PTC/HT(+) and patients with PTC/HT(-), and might provide new insights from the perspective of RNA for obtaining a further understanding of the clinical features related to PTC with HT.

show abstract

Epigenetic regulation of papillary thyroid carcinoma by long non-coding RNAs

Cited by 36 publications

References 78 publications

A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma

A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma

LncRNA GLTC targets LDHA for succinylation and enzyme activity to promote differentiated thyroid cancer progression and radioiodine resistance

Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto’s Thyroiditis

Contact Info

Product

Resources

About